Dramatic Response of BRAF V600E Mutant Papillary Craniopharyngioma to Targeted Therapy

We recently reported that BRAF V600E is the principal oncogenic driver of papillary craniopharyngioma, a highly morbid intracranial tumor commonly refractory to treatment. Here, we describe our treatment of a man age 39 years with multiply recurrent BRAF V600E craniopharyngioma using dabrafenib (150...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	JNCI : Journal of the National Cancer Institute 2016-02, Vol.108 (2), p.djv310
Hauptverfasser:	Brastianos, Priscilla K, Shankar, Ganesh M, Gill, Corey M, Taylor-Weiner, Amaro, Nayyar, Naema, Panka, David J, Sullivan, Ryan J, Frederick, Dennie T, Abedalthagafi, Malak, Jones, Pamela S, Dunn, Ian F, Nahed, Brian V, Romero, Javier M, Louis, David N, Getz, Gad, Cahill, Daniel P, Santagata, Sandro, Curry, Jr, William T, Barker, 2nd, Fred G
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Antineoplastic Combined Chemotherapy Protocols - therapeutic use Brief Communication Craniopharyngioma - drug therapy Craniopharyngioma - genetics Craniopharyngioma - pathology Craniopharyngioma - surgery Craniotomy Cytoreduction Surgical Procedures Drug Administration Schedule Glutamic Acid Humans Imidazoles - administration & dosage Magnetic Resonance Imaging Male Molecular Targeted Therapy - methods Mutation Neoplasm Recurrence, Local - drug therapy Neoplasm Recurrence, Local - genetics Neoplasm, Residual - surgery Oximes - administration & dosage Pituitary Neoplasms - drug therapy Pituitary Neoplasms - genetics Pituitary Neoplasms - pathology Pituitary Neoplasms - surgery Protein Kinase Inhibitors - administration & dosage Proto-Oncogene Proteins B-raf - antagonists & inhibitors Proto-Oncogene Proteins B-raf - genetics Pyridones - administration & dosage Pyrimidinones - administration & dosage Treatment Outcome Valine
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!